Key result
Ethinyl estradiol uniformly corrects abnormal lipid and lipoprotein profiles in post-MI patients.
Why the study?
The influence of sex hormones on abnormal circulating lipids and lipoproteins in myocardial infarction survivors was investigated to understand potential therapeutic effects.
Does ethinyl estradiol improve circulating lipid and lipoprotein concentrations in survivors of myocardial infarction?
Does ethinyl estradiol improve circulating lipid and lipoprotein concentrations in survivors of myocardial infarction?
Ethinyl estradiol corrects abnormal lipid profiles in myocardial infarction survivors, though it causes gynecomastia and decreased libido, and its long-term effect on clinical outcomes remains unknown.
May not support routine use given gynecomastia and unknown outcomes; leaves open effects on clinical events.
The administration of ethinyl estradiol to 100 survivors of myocardial infarction resulted in uniform correction of the abnormal circulating lipid and lipoprotein concentrations. Gynecomastia and depression of libido were well tolerated by the patients but were not ameliorated by an androgen preparation nor by a progesterone analogue. Methyl testosterone, which partly inhibited the estrogen effect, increased the concentration of cholesterol on the beta lipoprotein fraction. Progesterone had no significant effect on the circulating lipids and lipoproteins. Assessment of the effect of ethinyl estradiol on human atherogenesis must depend on long-term evaluation of its influence on morbidity and mortality rates.
No takes yet. Share an insight, caveat, or question.
Oliver et al. (1956) studied Myocardial infarction (n=100). Ethinyl estradiol was evaluated on Circulating lipid and lipoprotein concentrations. Ethinyl estradiol administration in survivors of myocardial infarction resulted in uniform correction of abnormal circulating lipid and lipoprotein concentrations.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: